



Educational sessions for Junior audience

**Monday, 5 February 2018**

<b>09:30-11:00</b> 90'	<b>Session 1</b> <b>The diseases</b>	<b>Chairs: To be announced</b>
25	The natural history of STS & GIST	Paolo. G Casali, IT
30'	The pathology of STS & GIST	A.Paolo Dei Tos, IT
30'	The "clinical" genetics of GIST	Maria Pantaleo, IT
15	Discussion	
11:00-11:30	Coffee Break	
<b>11:30-13:00</b> 90'	<b>Session 2</b> <b>Principles of local treatment</b>	<b>Chairs: To be announced</b>
30'	Surgical margins in STS & GIST	Peter Hohenberger, DE
30'	Principles of radiation therapy in STS	Rick L. Haas, NL
30'	Retroperitoneal sarcomas	Sylvie Bonvalot, FR
13:00-14:00	Lunch	
<b>14:00-15:00</b> 60'	<b>Session 3</b> <b>Multidisciplinary treatment in the localised-disease setting</b>	<b>Chairs: To be announced</b>
30'	Adjuvant chemotherapy of STS	Jean-Yves Blay, FR
30'	Adjuvant therapy of GIST	Heikki Joensuu, FI
15:00-15:30	Coffee Break	
<b>15:30-18:00</b> 150'	<b>Session 4</b> <b>The medical approach in the advanced-disease setting</b>	<b>Chairs: To be announced</b>
30'	Principles of systemic therapy of STS	Bernd Kasper, DE
30'	Histology- and molecularly-driven medical therapy of STS	Robin Jones, UK
30'	Targeted therapy of metastatic GIST	Peter Reichardt, DE
30'	Practical management of TKI treatment in GIST	Axel LeCense, FR
30'	Immune therapy of STS & GIST	Jean-Yves Blay, FR

Educational sessions for expert audience

**Monday, 5 February 2018**

<b>09:30-11:00 90'</b>	<b>Session 1 Localised GIST: Case discussions</b>	Moderators: To be announced
	Discussant: Alessandro Gronchi, IT	Panelists: To be announced
11:00-11:30	Coffee Break	
<b>11:30-13:00 90'</b>	<b>Session 2 Metastatic GIST: Case discussions</b>	Moderators: To be announced
	Discussant: Alessandro Gronchi, IT	Panelists: To be announced
13:00-14:00	Lunch	
<b>14:00-15:30 90'</b>	<b>Session 3 Localised STS: Case discussions</b>	Moderators: To be announced
	Discussant: Alessandro Gronchi, IT	Panelists: To be announced
15:30-16:00	Coffee Break	
<b>16:00-17:30 90'</b>	<b>Session 4 Metastatic STS: Case discussions</b>	Moderators: To be announced
	Discussant: Alessandro Gronchi, IT	Panelists: To be announced

## Tuesday, 6 February 2018

<b>08:00-08:30 30'</b>	<b>Opening &amp; Welcome</b>	<b>Chairs: To be announced</b>
10'	Welcome by ESMO	Paolo G. Casali, IT
10'	Welcome by INT - Milan	Giovanni Apolone, IT
10'	Welcome by SPAEN	Markus Wartenberg, DE

<b>08:30-09:50 80'</b>	<b>Session 1 – State of the art</b>	<b>Chairs: TBC</b>
20'	Pathology and genetics of STS	Christopher Fletcher, US
20'	The medical treatment of STS	Shreyas Patel, US
20'	The GIST genotypes relevant to therapy	Sebastian Bauer, DE
20'	The medical treatment of GIST	Heikki Joensuu, FI

09:50-10:20	Coffee Break
-------------	--------------

<b>10:20-12:30 130'</b>	<b>Session 2 - Surgery</b>	<b>Chairs: To be announced</b>
20'	Why is the “sarcoma” surgical margin different from the “epithelial”?	Chandrajit Raut, US
20'	Should we stratify the surgical margin across STS histologies?	Alessandro Gronchi, IT
20'	How the surgical margin has changed in retroperitoneal sarcomas?	To be announced
20'	When surgery should be done in desmoids?	Sylvie Bonvalot, FR
20'	Has surgery of lung metastases in sarcomas evolved from the XIX century on?	Peter Hohenberger, DE
20'	Is the GIST surgical margin different?	Piotr Rutkowski, PL
10'	Discussion	

12:30-13:30	Lunch
-------------	-------

13:30-14:30	Industry Satellite Symposium 1
-------------	--------------------------------

<b>14:40-16:10 90'</b>	<b>Session 3 – Radiation therapy</b>	<b>Chairs: To be announced</b>
20'	Does radiation therapy improve survival in STS?	Rick L. Haas, NL
20'	Is preoperative radiation therapy better?	To be announced
20'	Is there a rationale for radiation therapy in retroperitoneal sarcomas?	To be announced
20'	Should we use proton or carbon ion radiation therapy in any STS today?	Thomas F. DeLaney, US
10'	Discussion	

16:10-16:40	Coffee Break
-------------	--------------

## Tuesday, 6 February 2018, cont.

<b>16:40-18:50 140'</b>	<b>Session 4 - Chemotherapy</b>	
20'	Can we reach a consensus on the value of neoadjuvant & adjuvant chemotherapy in STS?	Robert S. Benjamin, US
20'	Can the pathologist say if a patient has responded to preoperative chemotherapy?	A. Paolo. Dei Tos, IT
20'	Can we get to an evidence-based histology-driven chemotherapy in advanced STS?	Paolo G. Casali, IT
20'	Are we prolonging survival with chemotherapy in metastatic STS?	Axel LeCesne, FR
20'	The case of uterine sarcomas	Suzanne George, US
20'	The case of histiocytic/dendritic cell neoplasms	Anna Maria Frezza, IT
20'	Discussion	

19:10-20:10	Industry Satellite Symposium 2
-------------	--------------------------------

## Wednesday, 7 February 2018

<b>08:00-10:50 170'</b>	<b>Session 5 – Targeted therapy of GIST &amp; STS</b>	<b>Chairs: To be announced</b>
20'	The clinical usefulness of profiling “wild-type” GIST	Jonathan Trent, US
20'	The clinical management of TKIs in GIST	Peter Reichardt, DE
20'	Current and future molecular biology of secondary resistance in GIST	Jonathan Fletcher, US
20'	Current and future approach to secondary resistance in GIST	George Demetri, US
20'	Actually actionable targets in STS	Patrick Schoffski, BE
20'	Histology-agnostic NGS for therapy in STS?	Andrew Wagner, US
20'	Can we get to an evidence-based targeted therapy of “rare” STS histologies?	Silvia Stacchiotti, IT
20'	Epigenetics and new avenues in STS	Mrinal Gounder, US
10'	Discussion	

10:50-11:20	Coffee break
-------------	--------------

<b>11:20-13.30 130'</b>	<b>Session 7 – Immune therapy</b>	<b>Chairs: To be announced</b>
20'	Will we get to an evidence-based immune therapy in STS?	Robert Maki, US
20'	Mutational load and immune microenvironment in STS and in the STS patient	Jean Yves Blay, FR
20'	Is there a rationale for immune therapy in GIST?	Ronald P. DeMatteo, US
20'	Should we combine immune therapy agents with what?	Sandra P. D'Angelo, US
20'	Next-generation immune therapy in STS	William Tap, US
20'	Will adoptive immune therapy be the way forward in “cold” STS?	Lee Helman, US
10'	Discussion	

13:30-14:30	Lunch
-------------	-------

14:20-15:20	Industry Satellite Symposium 3
-------------	--------------------------------

**Wednesday, 7 February 2018, cont.**

<b>15:30-17:25 115'</b>	<b>Session 8 – Round table with SPAEN</b>	<b>Chairs: To be announced</b>
15'	Does evidence-based medicine discriminate the sarcoma patient?	Paolo Bruzzi, IT
15'	A patient perspective	Speaker TBC
15'	Can we improve the pathologic diagnosis in STS?	A. Paolo. Dei Tos
15'	A patient perspective	Speaker TBC
15'	Will ERN improve quality of care of STS & GIST in the EU?	Paolo G. Casali
15'	A patient perspective	Speaker TBC
25'	Discussion	

<b>17:25-17:30 5'</b>	<b>Conclusions</b>	
5'	Take-home message: The value of multidisciplinary in STS & GIST	Paolo G. Casali